BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

Cara L HaymakerDepartment of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston, TXUSA

Richard C WuDepartment of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston, TXUSA;MD/PhD Program; University of Texas Medical School at Houston; Houston, TXUSA;Graduate Program in Immunology; University of Texas Graduate School of Biomedical Sciences; Houston, TXUSA;University of Texas Southwestern Medical Center; Department of Internal Medicine; Dallas, TXUSA

Krit RitthipichaiDepartment of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston, TXUSA;Graduate Program in Immunology; University of Texas Graduate School of Biomedical Sciences; Houston, TXUSA

Chantale BernatchezDepartment of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston, TXUSA;University of Texas Southwestern Medical Center; Department of Internal Medicine; Dallas, TXUSA

Marie-Andrée ForgetDepartment of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston, TXUSA

Jie Qing ChenDepartment of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston, TXUSA;Lion Biotechnologies; Tampa, FLUSA

Hui LiuInfectious Disease and Immunogenetics Section; Department of Transfusion Medicine; Clinical Center and trans-NIH Center for Human Immunology; National Institutes of Health; Bethesda, MDUSA

Ena WangInfectious Disease and Immunogenetics Section; Department of Transfusion Medicine; Clinical Center and trans-NIH Center for Human Immunology; National Institutes of Health; Bethesda, MDUSA;Sidra Medical Research Hospital; Doha, Qatar

Francesco MarincolaSurgery Branch; National Cancer Institute; National Institutes of Health; Bethesda, MDUSA;Department of Immunology; H Lee Moffitt Cancer Center; Tampa, FLUSA

Patrick HwuDepartment of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston, TXUSA;Lion Biotechnologies; Tampa, FLUSA

Laszlo G RadvanyiDepartment of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston, TXUSA;Lion Biotechnologies; Tampa, FLUSA;Department of Immunology; H Lee Moffitt Cancer Center; Tampa, FLUSACorrespondence[email protected]

show all

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

1014246_Supplementary_Materials.zip

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

1014246_Supplementary_Materials.zip

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date